Eris Lifesciences secures ₹45 crore term loan from Axis Bank
- Eris Lifesciences secured a ₹45 crore term loan from Axis Bank Limited
- The funds are designated to meet other liabilities as per the agreement
- The company stated the transaction will not impact expected net debt figures
- Axis Bank holds a charge on the company's brands as security for the loan
- Total outstanding term loans stand at ₹155.77 crore alongside ₹55 crore in working capital
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences has entered into a term loan agreement with Axis Bank Limited for ₹45 crore. The company disclosed the transaction on September 9, 2026, stating that the funds are intended to meet other liabilities.
The pharma services firm clarified that this is a routine financial adjustment and will not impact its expected net debt figure at the end of the quarter. The agreement was executed on September 9, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Loan Structure and Security
The total outstanding debt position reflects a mix of term loans and working capital facilities. Eris Lifesciences currently holds a term loan balance of ₹155.77 crore and a working capital loan of ₹55 crore.
Axis Bank will hold a charge on the company’s brands as security for this specific loan facility. There are no related-party transactions involved in this agreement, nor does the bank hold any shareholding in the company.
| Metric | Amount |
|---|---|
| New Term Loan | ₹45 crore |
| Existing Term Loan Outstanding | ₹155.77 crore |
| Working Capital Loan Outstanding | ₹55 crore |
What the Numbers Show
The disclosure highlights a significant reliance on brand equity as collateral. By securing a charge on its brands for the new ₹45 crore facility, Eris Lifesciences leverages its intangible assets to manage liquidity needs without altering its immediate net debt trajectory. This suggests a strategic approach to maintaining balance sheet flexibility while addressing short-term liability requirements.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.53% | -1.62% | -4.07% | -1.35% | -22.15% | +72.35% |
How might leveraging brand equity as collateral impact Eris Lifesciences' future ability to secure unsecured financing or negotiate favorable terms with other lenders?
Given the specific use of funds for 'other liabilities,' what underlying operational or strategic expenditures are driving this increased liquidity requirement?
Will the additional ₹45 crore term loan alter the company's debt-to-equity ratio significantly enough to affect its credit rating or interest coverage ratios in the upcoming fiscal year?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
